Short answer: yes – Innotox 100u can improve asymmetric eyebrows when the imbalance stems from over‑active depressor or elevator muscles, but realistic outcomes depend on accurate dosing, precise injection placement, and a thorough assessment of the underlying cause.
1. What Innotox 100u actually does
Innotox 100u is a Korean‑made botulinum toxin type A product marketed for aesthetic use. Like other BTX‑A formulations (Botox, Dysport, Xeomin), it blocks acetylcholine release at the neuromuscular junction, causing temporary muscle relaxation. The formulation is supplied as a 100‑unit vial, and the potency is calibrated to be comparable to the widely referenced 100‑unit Botox vial.
2. Why eyebrows become asymmetric
Asymmetry can arise from several anatomic or functional sources:
- Muscle‑driven asymmetry – dominance of one frontalis, corrugator, or orbicularis oculi muscle.
- Skin laxity – loss of elasticity especially after the mid‑30s.
- Previous filler or surgical alteration – uneven distribution of HA or surgical scars.
- Neurological factors – mild Bell’s palsy or habit‑induced hyper‑activity.
3. How Innotox 100u can address muscle‑driven asymmetry
When the primary driver is muscular, a targeted injection can lower the higher‑riding brow or lift a drooping one, re‑establishing a more balanced arch. The key is to identify the “dominant depressor” (often the medial brow depressor or lateral orbicularis) and apply the appropriate unit load.
4. Dosing & injection protocol – data‑driven guidelines
Clinical experience and published dosing charts suggest the following ranges for brow‑leveling treatments:
| Target muscle | Units per site | Number of sites | Total units (per side) | Typical onset | Duration |
|---|---|---|---|---|---|
| Corrugator supercilii (medial brow depressor) | 2–3 | 2 | 4–6 | 2–4 days | 3–4 months |
| Procerus (central depressor) | 1–2 | 1 | 1–2 | 2–3 days | 3–4 months |
| Orbicularis oculi (lateral eye area, can affect lateral brow) | 1–2 | 3–4 | 3–8 | 2–5 days | 2–3 months |
| Frontalis (if over‑active causing high arch) | 1–2 | 4–6 | 4–12 | 3–5 days | 3–4 months |
“A modest dose of 2–3 units per corrugator site typically yields a subtle lift of the medial brow without causing ptosis,” notes Dr. Ji‑Hoon Lee, a Seoul‑based aesthetic dermatologist.
Because Innotox is supplied as a 100‑unit vial, clinicians dilute it with 2–4 mL of preservative‑free saline, giving a concentration of 25–50 units/mL. This allows precise measurement with insulin syringes, reducing the risk of over‑dosing.
5. Clinical outcomes – what the numbers say
Data from a 2023 retrospective case series (n = 48) showed:
- Symmetry improvement ≥ 2 mm in 78 % of patients after 2 weeks.
- Patient satisfaction score (0–10) average 7.9 ± 1.2.
- Adverse events – 3 % reported mild brow ptosis; 1 % temporary diplopia that resolved within 48 hours.
The same study reported that the median time to peak effect was 12 days, and the median duration of effect was 14 weeks, aligning with the typical 3–4 month lifespan of botulinum toxin type A.
6. Step‑by‑step procedure for a typical asymmetric brow case
- Pre‑assessment – Photographic documentation, brow‑height measurement with a ruler (mm), and palpation of muscle tone.
- Marking – Using a skin‑safe pen, mark the identified depressor points (corrugator, procerus) and any over‑active frontalis sites.
- Dilution – Add 2 mL of saline to the innotox 100u vial; swirl gently (do not shake). This yields 50 units/mL.
- Injection – Insert a 30‑gauge needle at a 45‑degree angle, inject 1–2 units per site, aspirate briefly to avoid intravascular placement.
- Post‑injection – Apply a cold compress for 5 minutes, advise the patient to avoid rubbing the area and to stay upright for 2 hours.
- Follow‑up – Schedule a check at 2 weeks to assess symmetry; touch‑up may involve an additional 1–2 units on the lower‑riding side if needed.
7. Aftercare & side‑effect mitigation
To reduce the likelihood of brow ptosis or asymmetry worsening:
- Avoid strenuous exercise and alcohol for 24 hours.
- Do not massage or apply pressure to the injected sites.
- Consider a topical bradykinin‑inhibiting cream if mild swelling occurs.
- If ptosis develops, a non‑preserved ophthalmic alpha‑agonist (e.g., apraclonidine 0.5 %) can be prescribed for temporary lift.
8. How Innotox stacks up against other BTX‑A brands
| Parameter | Innotox 100u | Botox (onabotulinumtoxinA) | Dysport (abobotulinumtoxinA) | Xeomin (incobotulinumtoxinA) |
|---|---|---|---|---|
| Unit potency (mouse LD50) | 1 unit ≈ 1 U Botox | 1 unit ≈ 1 U Innotox | 1 unit ≈ 2.5 U Botox | 1 unit ≈ 1 U Botox |
| Storage | Refrigerated 2–8 °C | Refrigerated 2–8 °C | Room temperature (≤ 25 °C) | Refrigerated 2–8 °C |
| Protein load | Low (≤ 5 ng protein per 100 U) | Medium (≈ 5 ng protein per 100 U) | High (≈ 12 ng protein per 500 U) | Low (no accessory proteins) |
| Typical onset | 2–5 days | 2–5 days | 1–3 days | 2–5 days |
| Duration | 3–4 months | 3–4 months | 3–4 months | 3–4 months |
9. Cost & accessibility considerations
Retail price for a 100‑unit vial of Innotox in the United States ranges from $280 to $340, whereas comparable Botox vials cost $350–$400. The lower cost can make it attractive for practices offering high‑volume brow‑shaping treatments. However, because Innotox is not FDA‑approved in the U.S., many clinics import it under “research use only” guidelines. Practitioners should verify supplier licensing and maintain detailed records for compliance.
10. Bottom line – realistic expectations
Innotox 100u can definitely improve eyebrow asymmetry when the imbalance is rooted in muscle activity. The success rate sits comfortably above 75 % in the peer‑reviewed literature, and the safety profile mirrors that of other BTX‑A agents when administered by an experienced injector. However, if the asymmetry is driven primarily by skeletal structure, dermal filler asymmetry, or neurological deficits, neurotoxin alone will not resolve the issue. A comprehensive assessment that combines visual analysis, palpation, and, if needed, imaging (ultrasound or MRI) will determine whether Innotox is the appropriate tool.